Butobarbital
From Wikipedia, the free encyclopedia
|
|
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2009) |
| Systematic (IUPAC) name | |
|---|---|
| 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half-life | ? |
| Excretion | Renal |
| Identifiers | |
| CAS number | 77-28-1 |
| ATC code | N05CA03 |
| PubChem | CID 6473 |
| DrugBank | APRD00752 |
| ChemSpider | 6229 |
| UNII | OHZ8QAW6YC |
| KEGG | D02618 |
| ChEMBL | CHEMBL404422 |
| Chemical data | |
| Formula | C10H16N2O3 |
| Mol. mass | 212.246 |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Butobarbital, or butobarbitone, marketed as Butethal, Soneryl, and Neonal, is a hypnotic drug which is a barbiturate derivative. It was developed by Poulenc Brothers (now part of Rhône Poulenc) in 1921.[1]
[edit] References
- ^ DE Patent 481129
|
|||||||||||||||||||||||||||||
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |